One‐year clinical outcomes after sirolimus‐eluting coronary stent implantation in diabetics enrolled in the worldwide e‐SELECT registry. Issue 1 (27th May 2015)

• Record Type: Journal Article
• Authors: Bartorelli, Antonio L.; Egidy Assenza, Gabriele; Abizaid, Alexandre; Banning, Adrian; Džavík, Vladimír; Ellis, Stephen; Gao, Runlin; Holmes, David; Ho Jeong, Myung; Legrand, Victor; Neumann, Franz‐Josef; Spaulding, Christian; Worthley, Stephen G.; Urban, Philip
• Is Part Of: Catheterization and cardiovascular interventions. Volume 87:Issue 1(2016)
• Page Start: 52
• Page End: 62
• Publication Date: 2015-05-27
• Subjects: percutaneous coronary intervention -- sirolimus‐eluting stent -- diabetes mellitus -- stent thrombosis -- antithrombotic therapy -- bleeding complications; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.26026
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract : Background: Diabetes mellitus has worse outcome after percutaneous coronary intervention. Aim: We assessed stent thrombosis (ST), major adverse cardiac events (MACE), and major bleeding rates at 1 year after implantation of sirolimus‐eluting stents (SES) in patients with diabetes mellitus in a large multicenter registry. Methods: From May 2006 to April 2008, 15, 147 unselected consecutive patients were enrolled at 320 centers in 56 countries in a prospective, observational registry after implantation of ≥ 1 SES. Source data were verified in 20% randomly chosen patients at > 100 sites. Adverse events were adjudicated by an independent Clinical Event Committee. Results: Complete follow‐up at 1 year was obtained in 13, 693 (92%) patients, 4, 577 (30%) of whom were diabetics. Within diabetics, 1, 238 (9%) were insulin‐treated diabetics (ITD). Diabetics were older (64 vs. 62 years, P < 0.001), with higher incidence of major coronary risk factors, co‐morbidities, and triple‐vessel coronary artery disease. Coronary lesions had smaller reference vessel diameter (2.88 ± 0.46 vs. 2.93 ± 0.45 mm, P < 0.001) and were more often heavily calcified (26.1% vs. 22.6%, P < 0.001). At 1 year, diabetics had higher MACE rate (6.8% vs. 3.9%, P < 0.001) driven by ITD (10.6% vs. 5.5%, P < 0.001). Finally, diabetics had significant increase in ST (1.7% vs. 0.7%, P < 0.001), principally owing to ITD (3.4% vs. 1.1%, P < 0.001). There was an overall low risk of major bleeding during follow‐up, without significant difference among subgroups. Conclusions: In the e‐SELECT registry, diabetics represented 30% of patients undergoing SES implantation and had significantly more co‐morbidities and complex coronary lesions. Although 1‐year follow‐up documented good overall outcome in diabetics, higher ST and MACE rates were observed, mainly driven by ITD. © 2015 Wiley Periodicals, Inc.